Şahin O, Tatar B, Ekmekcioğlu C, Aliyev T, Odabaşı O. Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience. J Clin Exp Dent. 2020;12(8):e771-6.

doi:10.4317/jced.56837

_____________________

References

1. Gutta R, Louis P. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186-193. https://doi.org/10.1016/j.tripleo.2006.12.004 PMid:17448709

2. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks and preventive strategies. J Oral Maxillofac Surg. 2009;67:35-43. https://doi.org/10.1016/j.joms.2009.01.003 PMid:19371813

3. Reid IR, Bolland MJ, Grey AB. Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41:318-20. https://doi.org/10.1016/j.bone.2007.04.196 PMid:17572168

4. Şahin O, Odabaşı O, Aliyev T, Tatar B. Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. J Korean Assoc Oral Maxillofac Surg. 2019;45:108-15. https://doi.org/10.5125/jkaoms.2019.45.2.108 PMid:31106139 PMCid:PMC6502754

5. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136:1117-24. https://doi.org/10.1007/s00432-010-0907-7 PMid:20508948

6. Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43:847-54. https://doi.org/10.1016/j.jcms.2015.03.039 PMid:25958767

7. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012;41:1397-403. https://doi.org/10.1016/j.ijom.2012.06.020 PMid:22840716

8. Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radio 2014;117:e429-e435. https://doi.org/10.1016/j.oooo.2012.08.442 PMid:23182374

9. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49:2156-62. https://doi.org/10.1080/10428190802483778 PMid:19021059

10. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007;257:16-35. https://doi.org/10.1016/j.canlet.2007.07.007 PMid:17697748

11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1 PMid:12966493

12. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc. 2011;77:b147. PMid:22129778

13. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J. 2009;206:93-8. https://doi.org/10.1038/sj.bdj.2009.5 PMid:19165270

14. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410. https://doi.org/10.1016/j.joms.2007.08.003 PMid:18022461

15. Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30:231-9. https://doi.org/10.1007/s00198-018-4746-8 PMid:30406309

16. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg. 2010;68:2837-45. https://doi.org/10.1016/j.joms.2010.07.017 PMid:20971371

17. Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43:290-3. https://doi.org/10.1016/j.jcms.2014.11.014 PMid:25541255

18. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34. https://doi.org/10.1016/j.joms.2004.02.004 PMid:15122554

19. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839-47. https://doi.org/10.1016/j.joms.2008.01.026 PMid:18423269 PMCid:PMC2426967

20. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab. 2009;27:663-72. https://doi.org/10.1007/s00774-009-0090-6 PMid:19436946

21. Barba-Recreo P, Pardo DC, de Vera JL, Yébenes L, Burgueño M. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Craniomaxillofac Surg 2014;42:744-50. https://doi.org/10.1016/j.jcms.2013.11.005 PMid:24342733

22. Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg. 2016;44:1067-72. https://doi.org/10.1016/j.jcms.2016.05.004 PMid:27318752

23. Scoletta M, Arata V, Arduino PG, Lerda E, Chiecchio A, Gallesio G, et al. Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg. 2013;71:994-9. https://doi.org/10.1016/j.joms.2013.01.006 PMid:23434159

24. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012;48:817-21. https://doi.org/10.1016/j.oraloncology.2012.03.009 PMid:22483860

25. Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig. 2017;21:2165-72. https://doi.org/10.1007/s00784-016-2004-z PMid:27837344

26. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. IV. Clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e56-60. https://doi.org/10.1016/j.tripleo.2005.07.011 PMid:16504852

27. Hawkins D, Abrahamse H. Effect of multiple exposures of low-level laser therapy on the cellular responses of wounded human skin fibroblasts. Photomed Laser Surg. 2006;24:705-14. https://doi.org/10.1089/pho.2006.24.705 PMid:17199470

28. Kan B, Altay MA, Taşar F, Akova M. Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate. Lasers Med Sci. 2011;26:569-75. https://doi.org/10.1007/s10103-010-0816-7 PMid:20669038

29. Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R, et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013;18:e680-5. https://doi.org/10.4317/medoral.18812 PMid:23524436 PMCid:PMC3731098

30. Vescovi P, Meleti M, Merigo E, Meleti M, Manfredi M, Fornaini C, et al. Tooth Extractions in High-Risk Patients Under Bisphosphonate Therapy and Previously Affected With Osteonecrosis of the Jaws: Surgical Protocol Supported by Low-Level Laser Therapy. J Craniofac Surg. 2015;26:696-9. https://doi.org/10.1097/SCS.0000000000001665 PMid:25915674